These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31813092)

  • 1. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
    Evans M; Hicks D; Patel D; Patel V; McEwan P; Dashora U
    Diabetes Ther; 2020 Jan; 11(1):37-52. PubMed ID: 31813092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.
    Jones NK; Costello HM; Monaghan MT; Stewart K; Binnie D; Marks J; Bailey MA; Culshaw GJ
    Exp Physiol; 2023 Mar; 108(3):480-490. PubMed ID: 36644793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
    van Meijel LA; Tack CJ; de Galan BE
    Diabetes Obes Metab; 2021 Nov; 23(11):2582-2589. PubMed ID: 34338413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report.
    Tian Y; Hu W; Yan Q; Feng B
    Medicina (Kaunas); 2023 Apr; 59(5):. PubMed ID: 37241059
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments?
    Veneti S; Tziomalos K
    Expert Opin Pharmacother; 2021 Nov; 22(16):2261-2266. PubMed ID: 34402702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors.
    Evans M; Morgan AR; Yousef Z; Ellis G; Dashora U; Patel DC; Brown P; Hanif W; Townend JN; Kanumilli N; Moore J; Wilding JPH; Bain SC
    Drugs; 2021 Jul; 81(11):1243-1255. PubMed ID: 34160822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
    Wilding J; Fernando K; Milne N; Evans M; Ali A; Bain S; Hicks D; James J; Newland-Jones P; Patel D; Viljoen A
    Diabetes Ther; 2018 Oct; 9(5):1757-1773. PubMed ID: 30039249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
    Fioretto P; Giaccari A; Sesti G
    Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-insulin therapies in addition to insulin in Type 1 DM treatment.
    Llano A; McKay GA
    Br Med Bull; 2020 Jul; 134(1):54-62. PubMed ID: 32409841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 14. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
    Chen H; Birnbaum Y; Ye R; Yang HC; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1091-1108. PubMed ID: 34448973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
    Gordon J; Danne T; Beresford-Hulme L; Bennet H; Tank A; Edmonds C; Thorén F; Scheerer MF; McEwan P
    Diabetes Ther; 2020 May; 11(5):1135-1146. PubMed ID: 32274678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.